Tag Archives: Industry Personal

Why H&R Block Is Poised to Pull Back

By Brian D. Pacampara, The Motley Fool

Filed under:

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool’s free investing community, tax prep specialist H&R Block has received a distressing two-star ranking.

With that in mind, let’s take a closer look at H&R Block, and see what CAPS investors are saying about the stock right now.

H&R Block facts

   

Headquarters (founded)

Kansas City, Mo. (1946)

Market Cap

$7.8 billion

Industry

Personal services

Trailing-12-Month Revenue

$2.6 billion

Management

CEO William Cobb (since 2011)

CFO Gregory Macfarlane (since 2012)

Return on Equity (average, past 3 years)

49.9%

Cash/Debt

$418.4 million / $1.3 billion

Competitors

Intuit

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 34% of the 542 members who have rated H&R Block believe the stock will underperform the S&P 500 going forward.

Just yesterday, one of those Fools, ayekappy, highlighted H&R Block as a rather untimely opportunity:

Horrible company with a failing business model. Probably won’t be getting new customers and will lose a lot of existing customers due to their famous error and essentially lying about what % of people got their returns back already. They may have to hide under TaxAct to make people forget about their stained name. Next quarter’s numbers should be pretty ugly compared to normal since the glitch was heard about earlier in the tax season, so they already started bleeding customers this tax season.

While you can certainly make gains in mediocre companies with a little controversy surrounding them, the best investing approach is to choose great businesses and stick with them for the long term. The Motley Fool’s free report, “3 Stocks That Will Help You Retire Rich,” names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.

The article Why H&R Block Is Poised to Pull Back originally appeared on Fool.com.

Fool contributor Brian Pacampara has no position in any stocks mentioned. The Motley Fool recommends Intuit. The Motley Fool owns shares of Intuit. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

(function(c,a){window.mixpanel=a;var b,d,h,e;b=c.createElement(“script”);
b.type=”text/javascript”;b.async=!0;b.src=(“https:”===c.location.protocol?”https:”:”http:”)+
‘//cdn.mxpnl.com/libs/mixpanel-2.2.min.js’;d=c.getElementsByTagName(“script”)[0];
d.parentNode.insertBefore(b,d);a._i=[];a.init=function(b,c,f){function d(a,b){
…read more

Source: FULL ARTICLE at DailyFinance

Why Female Health Is Poised to Outperform

By Brian D. Pacampara, The Motley Fool

Filed under:

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool’s free investing community, female condom maker Female Health has earned a coveted five-star ranking.

With that in mind, let’s take a closer look at Female Health and see what CAPS investors are saying about the stock right now.

Female Health facts

 

 

Headquarters (founded)

Chicago, Ill. (1896)

Market Cap

$225.6 million

Industry

Personal products

Trailing-12-Month Revenue

$36.3 million

Management

Chairman/CEO O.B. Parrish

CFO Michele Greco

Return on Equity (average, past 3 years)

60.6%

Cash/Debt

$4.3 million/$0

Dividend Yield

3.3%

Competitors

Church & Dwight 

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 97% of the 333 members who have rated Female Health believe the stock will outperform the S&P 500 going forward.

Just last week, one of those Fools, All-Star BKITU, succinctly summed up the Female Health bull case for our community: “Decent financials, consumable product, lots of growth potential not only in industrializing countries, but in already-industrialized countries. That’s a rare treat these days.”

But while you can certainly make huge gains in exciting small-cap companies like Female Health, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool’s free report “3 Stocks That Will Help You Retire Rich” names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

 Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.

The article Why Female Health Is Poised to Outperform originally appeared on Fool.com.

Fool contributor Brian Pacampara has no position in any stocks mentioned, and neither does The Motley Fool. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

(function(c,a){window.mixpanel=a;var b,d,h,e;b=c.createElement(“script”);
b.type=”text/javascript”;b.async=!0;b.src=(“https:”===c.location.protocol?”https:”:”http:”)+
‘//cdn.mxpnl.com/libs/mixpanel-2.2.min.js’;d=c.getElementsByTagName(“script”)[0];
d.parentNode.insertBefore(b,d);a._i=[];a.init=function(b,c,f){function d(a,b){
var c=b.split(“.”);2==c.length&&(a=a[c[0]],b=c[1]);a[b]=function(){a.push([b].concat(
Array.prototype.slice.call(arguments,0)))}}var g=a;”undefined”!==typeof f?g=a[f]=[]:
f=”mixpanel”;g.people=g.people||[];h=[‘disable’,’track’,’track_pageview’,’track_links’,
‘track_forms’,’register’,’register_once’,’unregister’,’identify’,’alias’,’name_tag’,
‘set_config’,’people.set’,’people.increment’];for(e=0;e<h.length;e++)d(g,h[e]);
a._i.push([b,c,f])};a.__SV=1.2;})(document,window.mixpanel||[]);
mixpanel.init("9659875b92ba8fa639ba476aedbb73b9");

function addEvent(obj, evType, fn, useCapture){
if (obj.addEventListener){
obj.addEventListener(evType, fn, …read more
Source: FULL ARTICLE at DailyFinance

Why Herbalife Is Poised to Underperform

By Brian Pacampara, Pacampara, The Motley Fool

Filed under:

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool’s free investing community, nutritional-supplement network marketing company Herbalife has received an alarming one-star ranking.

With that in mind, let’s take a closer look at Herbalife and see what CAPS investors are saying about the stock right now.

Herbalife facts

   

Headquarters (founded)

Los Angeles, Calif. (1980)

Market Cap

$4.0 billion

Industry

Personal products

Trailing-12-Month Revenue

$4.1 billion

Management

Chairman/CEO Michael Johnson

CFO John DeSimone

Return on Capital (average, past 3 years)

45.2%

Cash/Debt

$333.5 million/$489.6 million

Dividend Yield

2.9%

Competitors

Amway

GNC Holdings

Wal-Mart Stores

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 32% of the 654 members who have rated Herbalife believe the stock will underperform the S&P 500 going forward.

Just yesterday, one of those Fools, All-Star Brettmj, succinctly summed up the Herbalife bear case for our community: “Overpriced products, even if it isn’t classified as a pyramid scheme this one will die off. [Underperform call] might go into the red for awhile but eventually people will come around to much better cheaper alternatives that don’t have questionable sales tactics.”

If you want market-topping returns, you need to protect yourself from any undue risk. Luckily, we’ve found another stock we are incredibly excited about — excited enough to dub it “The Motley Fool’s Top Stock for 2013.” We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won’t be here forever, so click here to access it now.

Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.

The article Why Herbalife Is Poised to Underperform originally appeared on Fool.com.

Fool contributor Brian Pacampara has no position in any stocks mentioned. The Motley Fool has the following options: long Jan. 2014 $50 calls on Herbalife. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

(function(c,a){window.mixpanel=a;var b,d,h,e;b=c.createElement(“script”);
b.type=”text/javascript”;b.async=!0;b.src=(“https:”===c.location.protocol?”https:”:”http:”)+
‘//cdn.mxpnl.com/libs/mixpanel-2.2.min.js’;d=c.getElementsByTagName(“script”)[0];
d.parentNode.insertBefore(b,d);a._i=[];a.init=function(b,c,f){function d(a,b){
var c=b.split(“.”);2==c.length&&(a=a[c[0]],b=c[1]);a[b]=function(){a.push([b].concat(
Array.prototype.slice.call(arguments,0)))}}var g=a;”undefined”!==typeof f?g=a[f]=[]:
f=”mixpanel”;g.people=g.people||[];h=[‘disable’,’track’,’track_pageview’,’track_links’,
‘track_forms’,’register’,’register_once’,’unregister’,’identify’,’alias’,’name_tag’,
‘set_config’,’people.set’,’people.increment’];for(e=0;e<h.length;e++)d(g,h[e]);
a._i.push([b,c,f])};a.__SV=1.2;})(document,window.mixpanel||[]);
mixpanel.init("9659875b92ba8fa639ba476aedbb73b9");

function addEvent(obj, evType, fn, useCapture){
…read more
Source: FULL ARTICLE at DailyFinance

Why Star Scientific Is Poised to Keep Plunging

By Brian Pacampara, Pacampara, The Motley Fool

Filed under:

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool’s free investing community, smokeless tobacco products specialist Star Scientific has received the dreaded one-star ranking.

With that in mind, let’s take a closer look at Star Scientific and see what CAPS investors are saying about the stock right now.

Star Scientific facts

Headquarters (founded)

Glen Allen, Va. (2000)

Market Cap

$300.0 million

Industry

Personal products

Trailing-12-Month Revenue

$5.4 million

Management

Chairman/President/COO Paul Perito
CEO Jonnie Williams

Trailing-12-Month Return on Equity

(136.3%)

Cash/Debt

$9.5 million / $12.0 thousand

Competitors

GlaxoSmithKline
Pfizer
Vector Group

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 45% of the 322 members who have rated Star Scientific believe the stock will underperform the S&P 500 going forward.

Just last week, one of those Fools, All-Star zzlangerhans, kindly updated our community on the opportunity:

So where does Star stand now? The patent infringement suit against big tobacco is gone for a paltry [$5M] settlement. I have to admit that one scared me a little. These are companies that have tens of billions in discretionary funds at their disposal to make irritants like Star go away forever. [$500M]? Chicken feed. So the fact that Star was only able to chisel out [$5M] is flat out pathetic.

The low-nitrosamine tobacco products are gone as well. So now Star only has unregulated cosmetics and nutraceuticals featuring snake oil anti-inflammatory compound anatabine. … Star can’t make anywhere near enough money off anatabine as a nutraceutical to justify its valuation, and the trials they are running to supposedly garner FDA approval as a drug are fraught with misrepresentation and will likewise fail.

Just a note: Virtually every one of my Star [underperform calls] has been followed shortly afterwards by a startling gap up in share price. Of course, I closed all those red thumbs for a solid positive score. So you might want to buy up some Star shares now but keep your finger on the trigger to sell on the spike.

If you want market-topping returns, you need to protect your portfolio from any undue risk, such as the macro trend that Warren Buffett referred to as “the tapeworm that’s eating at American competitiveness.” Find out what it is in our free report: “What’s Really Eating at America’s Competitiveness.” You’ll also discover an idea to profit as companies work to eradicate this efficiency-sucking tapeworm. Just click here for free, immediate access.

Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.

The article Why Star Scientific Is Poised to Keep Plunging originally appeared on Fool.com.

Fool contributor Brian Pacampara has no position in any stocks …read more
Source: FULL ARTICLE at DailyFinance